The AAIC 2026 Swedish real-world study shows a blood test for Alzheimer's pathology can raise diagnostic accuracy in routine care, while younger-onset families weigh that symptom-clarifying test against genetic testing for rare inherited causes. Blood biomarkers help explain current cognitive concerns in the person with symptoms; APP, PSEN1 or PSEN2 testing looks for a deterministic family mutation when early-age symptoms run with strong family history.
Blood biomarkers are measurable proteins in blood that signal disease processes. In this study, led by Lund neurologist Sebastian Palmqvist, the test measured amyloid-beta plus phosphorylated tau, proteins linked to Alzheimer's brain pathology. According to the Alzheimer's Association, the prospective study enrolled 1,310 patients with cognitive concerns and 165 physicians across primary and specialty care the Association's AAIC release.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Swedish study tested
- Why the results changed care plans
- Which blood tests have FDA clearance
- When genetic testing fits younger-onset families
What the Swedish study tested
The study examined how blood results change diagnosis in everyday practice, not in a highly selected trial clinic. Primary-care doctors and dementia specialists each made a diagnosis before and after seeing the blood result. The comparison focused on real referrals for memory and thinking concerns.
The design matters for families because younger-onset symptoms often enter care through a primary-care visit. A test that works in that setting can shorten the path to the right next step. It does not replace a full history, exam, and counseling.
Why the results changed care plans
After seeing blood results, primary-care doctors and dementia specialists each reached about 90% diagnostic accuracy. Diagnoses changed in one-third of patients and follow-up plans changed in over half. According to the Alzheimer's Association, those shifts were reported in the Association's AAIC release.
The test helped primary-care doctors most by ruling out Alzheimer's. A negative result allowed faster reassurance or referral for other causes of impairment. For families, that rule-out value can reduce waiting and focus attention on sleep, mood, medication, thyroid, hearing, or other brain conditions.
Which blood tests have FDA clearance
FDA cleared Fujirebio Lumipulse G pTau217/beta-Amyloid 1-42 on May 16, 2025 for adults 55 and older with cognitive signs. It showed 91.7% positive and 97.3% negative agreement with PET or spinal-fluid testing. According to the FDA, it is not for screening or standalone diagnosis, as described in the FDA approval notice.
FDA later cleared the Roche and Eli Lilly Elecsys pTau217 test to help rule in and rule out Alzheimer's. Labcorp and Quest planned to offer it after CE marking. The Alzheimer's Association also released a primary-care Decision Support Tool for appropriate blood-biomarker use on ALZPro, its clinician hub.
When genetic testing fits younger-onset families
Deterministic APP, PSEN1 or PSEN2 mutations cause under 1% of cases. They are a different option from blood biomarkers because they identify an inherited cause, not current pathology levels. According to the National Institute on Aging, testing is advised only for early-age symptoms plus strong family history, through a neurologist with pre- and post-test counseling the NIA genetics fact sheet.
Families can compare options by asking three practical questions with the doctor: Bring a symptom timeline, medication list, and family history with ages at onset. Ask whether a blood biomarker test, a neurology referral, or genetics counseling comes first. For suspected inherited disease, start with a neurologist and formal counseling rather than ordering a test alone.
- Is the goal to explain current symptoms, or to assess inherited risk for relatives
- Does the pattern show early-age onset plus multiple affected relatives across generations
- Is the person ready for counseling about results that affect family planning, work, and insurance concerns
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: How Younger-Onset Alzheimer’s Families Can Compare Testing Options
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Is Established and What Remains Uncertain for Younger-Onset Alzheimer’s Families
- The NIA 2026 Dementia Care and Caregiving Summit Report: What Changed and What Comes Next for Spouses and Partners
